ClinicalTrials.gg
Not yet recruitingNCT07583771Updated May 13, 2026

A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

A Phase 1 interventional study of CS08399 in Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer and Advanced Solid Tumors, sponsored by Chipscreen Biosciences, Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
186
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
544th of 1,594
186 · median 100
Started
2026
with 191 others
Phase 1
201 of 1,881
87 open now
Primary completion
2029-08
later than 898 of 986 live
Registered
1,767th of 1,881
by date

Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 544th largest by planned enrollment of the 1,594 interventional ones that give a count, is one of 192 that started in 2026, is one of 201 in phase 1, reaches primary completion later than 898 of the 986 other live ones, and was the 1,767th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion. The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of CS08399 in participants with MTAP-deleted solid tumors and Lymphoma, and to recommended Phase 2 dose(s) (RP2D) of CS08399 in appropriate tumor(s).

03

Conditions studied

  • Pancreatic Adenocarcinoma
  • Non Small Cell Lung Cancer
  • Advanced Solid Tumors
  • Lymphoma
  • Diffuse Large B-Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and sign the form voluntarily.
  2. ≥18 years old when signing the informed consent, regardless of sex.
  3. or cytologically confirmed locally advanced or solid tumors, or lymphoma, for which standard therapy has failed or is not tolerated, and no further standard therapy is available. Homozygous MTAP or CDKN2A deletion confirmed by tissue or peripheral blood testing.
  4. For glioblastoma: at least one measurable intracranial tumor lesion according to the RANO 2.0 criteria. For other solid tumors: at least one according to v1.1 criteria. For lymphoma: at least one measurable lesion according to Lugano 2014 criteria.
  5. For glioblastoma: score ≥60. For other solid tumors and lymphoma: performance status of 0 or 1.
  6. Adequate organ function.
  7. ≥3 months.
  8. Able to swallow and retain oral study medication.

Exclusion criteria

Exclusion Criteria:

  1. Received any anti-tumor therapy (including but not limited to chemotherapy, targeted therapy, anti angiogenic therapy, immunotherapy, cell therapy, radiotherapy, tumor embolization, etc.) or experimental drugs/devices that have not been approved for marketing within 28 days prior to the first dose or are still within 5 half-lives of such drugs (whichever is shorter).
  2. Previously received MAT2A or PRMT5 inhibitors.
  3. Underwent major surgery (cranial, thoracic, or abdominal) within 28 days prior to the first dose or have unresolved wounds, ulcers, or fractures.
  4. Have unresolved toxicities from previous treatments that have not recovered to v5.0 grade ≤1.
  5. History of other primary within 5 years prior to the first dose.
  6. For solid tumors : The presence of active, clinically symptomatic central nervous system or or spinal cord compression at screening.
  7. Primary central nervous system lymphoma or systemic lymphoma with CNS involvement.
  8. Evidence of interstitial lung disease, pulmonary fibrosis, or non-infectious pneumonitis requiring treatment on chest imaging at screening.
  9. Active infection requiring systemic anti-infective treatment at screening.
  10. Received drainage of pleural effusion, ascites, or pericardial effusion within 1 month prior to the first dose or have significant clinical symptoms.
  11. Uncontrolled or significant cardiovascular disease.
  12. Poorly controlled diabetes.
  13. Significant gastrointestinal abnormalities at screening that may affect drug intake, transport, or absorption.
  14. History of gastrointestinal perforation, fistula, peptic ulcer, bowel obstruction, or biliary obstruction within 6 months prior to the first dose.
  15. hemoptysis or tumor bleeding within 14 days prior to the first dose; significant active bleeding within 2 months prior to the first dose; currently on anticoagulants; high-risk bleeding tendency at screening.
  16. Serious thromboembolic events within 6 months prior to the first dose.
  17. Active tuberculosis at screening.
  18. Active or at screening. infection or syphilis infection at screening.
  19. Allergy or to any component of the trial drug or known , or history of severe allergic diseases.
  20. History of organ transplantation or hematopoietic stem cell transplantation.
  21. History of alcohol abuse or drug abuse.
  22. Any psychiatric or cognitive disorder that may limit understanding of , compliance with the protocol, or participation in the trial.
  23. Pregnant or breastfeeding women.
  24. Other conditions deemed unsuitable for participation in this trial by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    CS08399

    two phases: dose escalation and cohort expansion. The dose escalation part is further divided into single-dose and multiple-dose administration. In the cohort expansion part, only multiple doses.

    Drug: CS08399

Interventions

  • DrugCS08399

    Oral tablet. Only one dose on C0D1 in single-dose period. Once or twice daily from C1D1 until disease progression, death, intolerable toxicity, loss to follow-up, withdrawal of informed consent, or the end of the trial, whichever occurs first, in multiple-dose period in both escalation and cohort expansion phases.

06

What researchers measure

Primary outcomes

  1. incidence of dose-limiting toxicity (DLT)

    Time frame: 34 days after, that is 6 days after single-dose and 28 days after first administration in multiple-dose

  2. maximum tolerated dose (MTD)

    Time frame: dose escalation part, up to approximately 2 year

  3. incidence of adverse events (AEs)

    Number of participants with AE(s)

    Time frame: from first administration to 28 days after last administration or next anti-tumor therapy, whichever occurs first

  4. Pharmacokinetic parameters: Time to Maximum Concentration (Tmax)

    Time frame: during treatment, up to approximately 2 year

  5. Pharmacokinetic parameters: Maximum Concentration (Cmax)

    Time frame: during treatment, up to approximately 2 year

  6. Pharmacokinetic parameters: Area Under the Concentration-time Curve(AUC)

    Time frame: during treatment, up to approximately 2 year

  7. Pharmacokinetic parameters: Trough Concentration (Ctrough)

    Time frame: during treatment, up to approximately 2 years

  8. Pharmacokinetic parameters: Accumulation Ratio (Rac)

    Time frame: during treatment, up to approximately 2 years

  9. Pharmacokinetic parameters: Elimination Half-life (t1/2)

    Time frame: during treatment, up to approximately 2 years

  10. Pharmacokinetic parameters: Clearance over Fractional Bioavailability (CL/F)

    Time frame: during treatment, up to approximately 2 years

  11. Pharmacokinetic parameters: Volume of Distribution at Steady State over Fractional Bioavailability (Vz/F)

    Time frame: during treatment, up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Up to approximately 4 years

  2. Disease control rate (DCR)

    Time frame: Up to approximately 4 years

  3. Duration of Response (DOR)

    Time frame: Up to approximately 4 years

  4. Time to Progression (TTP)

    Time frame: Up to approximately 4 years

  5. Time to Response (TTR)

    Time frame: Up to approximately 4 years

  6. progression-free survival (PFS)

    Time frame: Up to approximately 4 years

  7. Overall Survival (OS)

    Time frame: Up to approximately 4 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Aug 2029, 38 months later.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 38 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartEst.
Jun 2026
Primary completionEst.
Aug 2029
CompletionEst.
Jan 2030
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07583771
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Jun 2026 (estimated)
Primary completion
Aug 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
May 13, 2026

Study contacts

Xuelian Zhou
Contact
zhouxuelian@chipscreen.com
028-64907337

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion